Berendsen H H, de Leij L, Poppema S, Postmus P E, Boes A, Sluiter H J, The H
Department of Clinical Immunology, University Hospital, Groningen, The Netherlands.
J Clin Oncol. 1989 Nov;7(11):1614-20. doi: 10.1200/JCO.1989.7.11.1614.
In most cases of small-cell lung carcinomas (SCLC) phenotypic features compatible with a neuroendocrine differentiation status can be identified by monoclonal (MOC) antibody-based immunohistological procedures. Similar features can be recognized only in a minority of non-SCLC tumors. During a period of 30 months, all diagnostic non-SCLC biopsies (141 cases) were prospectively analysed for the presence of markers indicative for neuroendocrine differentiation. In 31% of all cases, such a presence could be noticed. Neuroendocrine differentiation (50% to 100% positive-staining tumor cells) was recognized more frequently in adenocarcinoma when compared to large-cell and squamous-cell carcinoma (chi 2 = 9.31, 2 degrees of freedom, P less than 0.01). To investigate whether the clinical behavior of these "neuroendocrine" non-SCLC cases mimics SCLC, a multivariate analysis for prognostic factors was performed. Among other prognostic factors, biopsies containing more than 50% positive-staining tumor cells with the MOC antibody-1 (MOC-1) were recognized as negative prognostic factors.
在大多数小细胞肺癌（SCLC）病例中，基于单克隆（MOC）抗体的免疫组织学方法可识别出与神经内分泌分化状态相符的表型特征。类似特征仅在少数非小细胞肺癌肿瘤中可被识别。在30个月的时间里，对所有诊断性非小细胞肺癌活检样本（141例）进行前瞻性分析，以检测是否存在指示神经内分泌分化的标志物。在所有病例的31%中，可观察到此类标志物的存在。与大细胞癌和鳞状细胞癌相比，腺癌中神经内分泌分化（50%至100%阳性染色肿瘤细胞）的识别更为频繁（χ2 = 9.31，自由度为2，P < 0.01）。为研究这些“神经内分泌”非小细胞肺癌病例的临床行为是否类似于小细胞肺癌，对预后因素进行了多变量分析。在其他预后因素中，含有超过50% MOC抗体-1（MOC-1）阳性染色肿瘤细胞的活检样本被识别为不良预后因素。
